{"id":"na-ve-patients-mndl-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5077405","moleculeType":"Unknown","molecularWeight":"377.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of MNDL therapy is not well understood, but it is believed to involve the inhibition of a specific enzyme involved in the progression of liver disease. This inhibition leads to a reduction in liver inflammation and fibrosis, ultimately slowing the progression of liver disease.","oneSentence":"MNDL therapy involves the use of a specific compound to target and modulate the activity of a particular enzyme.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:24.503Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of non-alcoholic steatohepatitis (NASH)"}]},"trialDetails":[{"nctId":"NCT05184491","phase":"PHASE4","title":"Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2021-10-15","conditions":"Helicobacter Pylori","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Naïve patients - MNDL therapy","genericName":"Naïve patients - MNDL therapy","companyName":"National Liver Institute, Egypt","companyId":"national-liver-institute-egypt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MNDL therapy involves the use of a specific compound to target and modulate the activity of a particular enzyme. Used for Treatment of non-alcoholic steatohepatitis (NASH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}